TRANSCODE THERAPEUTICS INC (RNAZ) Stock Price, Quote, News and Overview
NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD
RNAZ Quote, Performance and Key Statistics
0.2725
-0.08 (-23.58%)
The current stock price of RNAZ is 0.2725 USD. In the past month the price decreased by -64.61%. In the past year, price decreased by -98.3%.
RNAZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About RNAZ
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-04-28. The firm is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
Company Info
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS US
CEO: Robert Michael Dudley
Employees: 10
Company Website: https://www.transcodetherapeutics.com/
Investor Relations: https://ir.transcodetherapeutics.com/
Phone: 18573016857
TRANSCODE THERAPEUTICS INC / RNAZ FAQ
What is the stock price of TRANSCODE THERAPEUTICS INC today?
The current stock price of RNAZ is 0.2725 USD. The price decreased by -23.58% in the last trading session.
What is the ticker symbol for TRANSCODE THERAPEUTICS INC stock?
The exchange symbol of TRANSCODE THERAPEUTICS INC is RNAZ and it is listed on the Nasdaq exchange.
On which exchange is RNAZ stock listed?
RNAZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TRANSCODE THERAPEUTICS INC stock?
7 analysts have analysed RNAZ and the average price target is 20.4 USD. This implies a price increase of 7386.24% is expected in the next year compared to the current price of 0.2725. Check the TRANSCODE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRANSCODE THERAPEUTICS INC worth?
TRANSCODE THERAPEUTICS INC (RNAZ) has a market capitalization of 6.36M USD. This makes RNAZ a Nano Cap stock.
How many employees does TRANSCODE THERAPEUTICS INC have?
TRANSCODE THERAPEUTICS INC (RNAZ) currently has 10 employees.
Should I buy TRANSCODE THERAPEUTICS INC (RNAZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNAZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNAZ, evaluating the profitability, health, valuation and growth aspects
- TRANSCODE THERAPEUTICS INC (RNAZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRANSCODE THERAPEUTICS INC (RNAZ) Sales and EPS estimates to see what analysts future expectations are.
- TRANSCODE THERAPEUTICS INC (RNAZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRANSCODE THERAPEUTICS INC (RNAZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRANSCODE THERAPEUTICS INC (RNAZ) Stock Chart to make your own analysis
- TRANSCODE THERAPEUTICS INC (RNAZ) Latest news and press-releases to stay up to date.
Does TRANSCODE THERAPEUTICS INC (RNAZ) stock pay dividends?
RNAZ does not pay a dividend.
What is the Price/Earnings (PE) ratio of TRANSCODE THERAPEUTICS INC (RNAZ)?
TRANSCODE THERAPEUTICS INC (RNAZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-69.7).
What is the Short Interest ratio of TRANSCODE THERAPEUTICS INC (RNAZ) stock?
The outstanding short interest for TRANSCODE THERAPEUTICS INC (RNAZ) is 77.28% of its float. Check the ownership tab for more information on the RNAZ short interest.
RNAZ Technical Analysis
RNAZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNAZ. The financial health of RNAZ is average, but there are quite some concerns on its profitability.
RNAZ Financial Highlights
Over the last trailing twelve months RNAZ reported a non-GAAP Earnings per Share(EPS) of -69.7. The EPS increased by 95.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -204.75% | ||
| ROE | -325.62% | ||
| Debt/Equity | 0 |
RNAZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RNAZ. The Buy consensus is the average rating of analysts ratings from 7 analysts.